What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
Paolo A. Ascierto spends much of his time researching Internal medicine, Melanoma, Ipilimumab, Oncology and Surgery.
His research links Gastroenterology with Internal medicine.
His work carried out in the field of Melanoma brings together such families of science as Pembrolizumab, Cancer, Survival analysis and Immunology.
He has researched Ipilimumab in several fields, including Expanded access and Adjuvant therapy, Chemotherapy, Dacarbazine.
In his research, Performance status and Neuroblastoma RAS viral oncogene homolog is intimately related to Binimetinib, which falls under the overarching field of Oncology.
The Surgery study which covers Adverse effect that intersects with Asymptomatic.
His most cited work include:
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation (5698 citations)
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. (4552 citations)
- Nivolumab in previously untreated melanoma without BRAF mutation. (3334 citations)
What are the main themes of his work throughout his whole career to date?
Paolo A. Ascierto mainly focuses on Internal medicine, Melanoma, Oncology, Ipilimumab and Cancer.
His Internal medicine research focuses on Surgery and how it relates to Gastroenterology.
His research integrates issues of Clinical trial, Pathology and Immunology in his study of Melanoma.
His Clinical trial study combines topics from a wide range of disciplines, such as Adjuvant and Randomized controlled trial.
His Oncology study deals with Pembrolizumab intersecting with Placebo.
Paolo A. Ascierto has included themes like Expanded access, Clinical endpoint and Adverse effect in his Ipilimumab study.
He most often published in these fields:
- Internal medicine (58.05%)
- Melanoma (55.54%)
- Oncology (45.05%)
What were the highlights of his more recent work (between 2019-2021)?
- Internal medicine (58.05%)
- Oncology (45.05%)
- Melanoma (55.54%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Internal medicine, Oncology, Melanoma, Immunotherapy and Cancer.
In the field of Internal medicine, his study on Clinical trial, Nivolumab, Pembrolizumab and Ipilimumab overlaps with subjects such as In patient.
While the research belongs to areas of Pembrolizumab, Paolo A. Ascierto spends his time largely on the problem of Placebo, intersecting his research to questions surrounding Cobimetinib and Hazard ratio.
His research in Ipilimumab intersects with topics in Clinical endpoint and Adverse effect.
Paolo A. Ascierto focuses mostly in the field of Oncology, narrowing it down to matters related to Vemurafenib and, in some cases, Atezolizumab and MAPK/ERK pathway.
His Melanoma research includes themes of Targeted therapy and Adjuvant therapy.
Between 2019 and 2021, his most popular works were:
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. (325 citations)
- Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. (79 citations)
- Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial (78 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
Paolo A. Ascierto mainly investigates Internal medicine, Oncology, Melanoma, Clinical trial and In patient.
His study in Cancer, Ipilimumab, Hazard ratio, Nivolumab and Pembrolizumab falls within the category of Internal medicine.
Paolo A. Ascierto works mostly in the field of Ipilimumab, limiting it down to topics relating to Clinical endpoint and, in certain cases, Adverse effect.
His Oncology research is multidisciplinary, relying on both Metastatic melanoma, Chemotherapy, Confidence interval and Immunotherapy.
His work in the fields of Melanoma, such as Binimetinib, overlaps with other areas such as Context.
His study in Clinical trial is interdisciplinary in nature, drawing from both Survival analysis and Dabrafenib.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
